文献速递产科

再次剖宫产前的B族链球菌筛查:一项成本效果分析

Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis.
PubMed 文献 · Obstet Gynecol · 2017-01-01

该决策分析从医疗保健角度评估单胎妊娠计划再次剖宫产妇女普遍B族链球菌(GBS)筛查的成本效果。基础案例中普遍筛查每获得一个新生儿质量调整生命年需花费114,445美元,超过100,000美元阈值,不具成本效果;当GBS阳性率>28%、计划剖宫产前临产比例>29%或最终经阴道分娩比例>10%时,筛查变得具有成本效果。

要点

  • 基础案例下普遍GBS筛查每获得一个新生儿QALY花费114,445美元,超过100,000美元阈值,不具成本效果。
  • 预防一例GBS不良结局的成本超过400,000美元。
  • 当GBS阳性率>28%、临产比例>29%或阴道分娩比例>10%时,普遍筛查具成本效果。

核心结论

  • 对计划再次剖宫产的单胎妊娠妇女普遍进行GBS筛查在所有人群中可能不具成本效果,但在GBS高流行、临产风险高或最终可能选择阴道分娩的人群中可能具成本效果。

研究设计与样本

  • 从医疗保健角度进行的决策分析,比较计划再次剖宫产妇女普遍GBS筛查与不筛查的成本效果。
  • 假设GBS定植率为25%,26.6%的妇女在妊娠35周至计划剖宫产时间之间临产,3.3%计划再次剖宫产者最终经阴道分娩。
  • 主要结局为每获得一个新生儿质量调整生命年(QALY)的成本,成本效果阈值为每QALY 100,000美元。
  • 新生儿生活质量采用五种健康状态(健康、轻度、中度或重度残疾、死亡)评估,健康新生儿预期寿命为79年。
  • 采用单因素敏感性分析和蒙特卡罗分析评估结果。

主要发现

  • 基础案例中,普遍GBS筛查与不筛查相比不具成本效果,每获得一个新生儿QALY花费114,445美元。
  • 预防一例GBS不良结局的成本超过400,000美元。
  • 若GBS阳性率大于28%、计划分娩前临产比例大于29%或经阴道分娩比例大于10%,普遍筛查变得具有成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the cost-effectiveness of universal group B streptococci (GBS) screening in women with a singleton pregnancy planning a repeat cesarean delivery. METHODS: We conducted a decision analysis from a health care perspective to compare the cost-effectiveness of GBS screening for women planning a repeat cesarean delivery. With universal screening, all GBS-positive women who labored before a scheduled cesarean delivery received antibiotic prophylaxis. With no screening, women who presented in labor received antibiotics based on risk-based criteria. Neonates born to women colonized with GBS were at risk for early-onset GBS disease, disability, and death. We assumed a GBS prevalence of 25%, that 26.6% of women labored between 35 weeks of gestation and their scheduled time for cesarean delivery, and that 3.3% who planned a repeat cesarean delivery instead delivered vaginally. The primary outcome was cost per neonatal quality-adjusted life-year gained, with a cost-effectiveness threshold of $100,000 per quality-adjusted life-year. Neonatal quality of life was assessed using five health states (healthy, mild, moderate, or severe disability, and death) with a life expectancy of 79 years for healthy neonates. One-way sensitivity and Monte Carlo analyses were used to evaluate the results. RESULTS: In the base case, universal GBS screening in women planning a repeat cesarean delivery was not cost-effective compared with no screening, costing $114,445 per neonatal quality-adjusted life-year gained. The cost to prevent an adverse outcome from GBS exceeded $400,000. If greater than 28% of women were GBS-positive, greater than 29% labored before their scheduled delivery, or greater than 10% delivered vaginally, universal screening became cost effective. CONCLUSION: Universal GBS screening in women with a singleton pregnancy planning a repeat cesarean delivery may not be cost-effective in all populations. However, in populations with a high GBS prevalence, women at high risk of laboring before their scheduled cesarean delivery, or women who may ultimately opt for a vaginal delivery, GBS screening may be cost effective.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Albright CM, MacGregor C, Sutton D, et al. Group B Streptococci Screening Before Repeat Cesarean Delivery: A Cost-Effectiveness Analysis. Obstet Gynecol. 2017. PMID: 27926650. doi:10.1097/AOG.0000000000001800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。